Characterization of a T cell dysfunctional state induced in mice with AML

描述（由申请人提供）：肿瘤抗原特异性T细胞的初始活化由宿主树突状细胞（DC）调节。最近，人们观察到，垂死的癌细胞产生的“危险信号”激活了局部宿主DC，然后能够启动适应性抗肿瘤T细胞反应。这些观察结果澄清了我们对肿瘤抗原特异性T细胞如何被激活以对抗作为固体团块生长的癌症的理解。然而，控制肿瘤抗原特异性T细胞在血液学癌症宿主中的激活与抑制的过程仍然是难以捉摸的。血液学癌症以播散模式生长，缺乏典型的“引流”淋巴结。我们实验室的长期目标是在基本水平上解开这些机制，我们相信这将对指导未来白血病有效免疫疗法的发展非常重要。我们在小鼠急性髓性白血病（AML）模型中的工作表明，当白血病细胞静脉注射（IV）到小鼠体内时，抗原特异性T细胞功能障碍迅速发生，而皮下（SC） AML细胞接种导致T细胞启动成功，这表明血液学癌症与实体癌症激活宿主免疫系统的能力存在根本差异。因此，我们假设在耐受性DC诱导的AML宿主中存在与T细胞能量或缺失相一致的抗原特异性T细胞功能障碍状态，并提出以下具体目的：(1)确定小鼠AML模型中诱导的抗原特异性T细胞功能障碍的机制；(2)鉴定AML小鼠T细胞功能障碍的细胞介质；(3)确定针对宿主DC激活的策略，以预防或逆转AML小鼠的T细胞功能障碍。为了实现这些目标，我们建立了一个临床前AML模型。C1498小鼠AML细胞系已被设计表达一种模型抗原，该抗原可被T细胞受体转基因CD8+ T细胞识别（2C）。我们将仔细分析IV和SC C1498细胞接种后小鼠2C T细胞的增殖和功能，以确定T细胞功能障碍的机制。为了鉴定可能调节T细胞功能障碍的细胞，将荧光标记的C1498细胞IV接种到小鼠体内，并利用免疫荧光和共聚焦显微镜确定哪些DC亚群吞噬了次级淋巴器官中垂死的C1498细胞。然后将特定DC群体作为清除目标，以确定在AML小鼠中诱导T细胞功能障碍的最终原因。最后，将探索针对宿主DC激活的临床相关策略，以确定哪种策略可以逆转AML小鼠的T细胞功能障碍。这些研究将有助于我们理解血液学癌症如何促进免疫逃避。此外，针对免疫耐受逆转的方法将进行测试，可能导致对临床转化有用的策略。因此,

DESCRIPTION (provided by applicant): The initial activation of tumor antigen-specific T cells is regulated by host dendritic cells (DC). Recently, it has been observed that "danger signals" produced by dying cancer cells activate local host DC, which are then able to prime adaptive anti-tumor T cell responses. These observations have clarified our understanding of how tumor antigen-specific T cells are activated against cancers which grow as a solid mass. However, the processes which govern the activation versus suppression of tumor antigen-specific T cells in hosts with hematological cancers, which grow in a disseminated pattern and lack a classical "draining" lymph node, remain elusive. The long-term goal of our laboratory is to unravel these mechanisms at a basic level, which we believe will be important to guide the development of effective immunotherapy for leukemia in the future. Our work in a murine acute myeloid leukemia (AML) model has revealed that when leukemia cells are introduced into mice intravenously (IV), antigen-specific T cell dysfunction rapidly ensues, whereas a subcutaneous (SC) AML cell inoculation leads to successful T cell priming, arguing that a fundamental difference exists between the ability of hematological versus solid cancers to activate the host immune system. Thus, we hypothesize that a state of antigen-specific T cell dysfunction, consistent with T cell anergy or deletion, occurs in hosts with AML, which is induced by tolerogenic DC, and propose the following Specific Aims: (1) To identify the mechanism of antigen-specific T cell dysfunction induced in a murine AML model; (2) To identify the cellular mediators of T cell dysfunction in mice with AML; and (3) to identify strategies targeting activation of host DC to prevent or reverse T cell dysfunction in mice with AML. To address these aims, we have generated a pre-clinical AML model. The C1498 murine AML cell line has been engineered to express a model antigen which is recognized by a T cell receptor transgenic CD8+ T cell (2C). The proliferation and function of 2C T cells in mice following IV versus SC C1498 cell inoculation will be carefully analyzed to identify the mechanism of T cell dysfunction. To identify the cell(s) which may regulate T cell dysfunction, fluorescently-labeled C1498 cells will be inoculated IV into mice, and immunofluorescence and confocal microscopy will be utilized to identify which DC subset(s) engulf dying C1498 cells in secondary lymphoid organs. Specific DC populations will then be targeted for depletion to determine which is ultimately responsible for inducing T cell dysfunction in mice with AML. Lastly, clinically-relevant strategie targeting host DC activation will be explored to determine which can reverse T cell dysfunction in mice with AML. These studies will contribute to our understanding of how hematological cancers promote immune evasion. Additionally, approaches targeting the reversal of immune tolerance will be tested, possibly leading to strategies useful for clinical translation. Thus, the knowledge to be gained is important from a biological standpoint, and also is expected to lead to immunotherapeutic approaches for patients with AML in the future.